List of Excipients in Branded Drug CHOLETEC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bracco Diagnostics Inc	CHOLETEC	mebrofenin	0270-0083	METHYLPARABEN
Bracco Diagnostics Inc	CHOLETEC	mebrofenin	0270-0083	PROPYLPARABEN
Bracco Diagnostics Inc	CHOLETEC	mebrofenin	0270-0083	STANNOUS FLUORIDE

CHOLETEC Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

CHOLETEC is a technetium Tc 99m-labeled diagnostic radiopharmaceutical kit containing mebrofenin and stannous chloride dihydrate. Its commercial value depends less on conventional excipient differentiation than on radiolabeling reliability, kit stability, technetium availability, manufacturing continuity, and hospital workflow integration. The clearest opportunities are supply-chain resilience, alternative kit manufacturing, improved lyophilized formulations, radiopharmacy distribution, and complementary hepatobiliary imaging services.

What is CHOLETEC and how is it used?

CHOLETEC is a sterile, nonpyrogenic, lyophilized kit used to prepare technetium Tc 99m mebrofenin injection for hepatobiliary imaging. After reconstitution with sodium pertechnetate Tc 99m injection, the product is administered intravenously and images are acquired with a gamma camera.

The principal clinical use is evaluation of the liver, biliary system, gallbladder, and related hepatobiliary function. The FDA labeling identifies hepatobiliary imaging as the approved indication and describes use in adults and pediatric patients [1].

Attribute	CHOLETEC profile
Brand	CHOLETEC
Active imaging agent	Technetium Tc 99m mebrofenin
Nonradioactive kit component	Mebrofenin
Reducing agent	Stannous chloride dihydrate
Final radiolabeled product	Technetium Tc 99m mebrofenin
Dosage form	Lyophilized powder for solution
Administration	Intravenous
Clinical field	Nuclear medicine and hepatobiliary imaging
Preparation site	Nuclear pharmacy, hospital radiopharmacy, or approved radiopharmaceutical facility
Radioisotope source	Sodium pertechnetate Tc 99m injection
Primary commercial constraint	Reliable preparation and time-sensitive distribution

The product is not administered in its kit form. The kit is labeled with technetium Tc 99m before clinical use. This distinction determines the excipient strategy, regulatory pathway, and commercial model.

What excipients are used in CHOLETEC?

The principal formulation components identified in the FDA prescribing information are mebrofenin and stannous chloride dihydrate. The label identifies each vial as containing 45 mg of mebrofenin and 0.50 mg of stannous chloride dihydrate, with the tin content controlled within the specified limit [1].

CHOLETEC formulation composition

Component	Function	Commercial relevance
Mebrofenin	Ligand that forms the technetium Tc 99m complex	Determines hepatobiliary uptake and imaging performance
Stannous chloride dihydrate	Reducing agent that converts technetium to a labeling-compatible oxidation state	Critical to radiochemical yield and product consistency
Lyophilized matrix	Preserves the nonradioactive kit during storage	Supports shelf life and distribution
Sodium pertechnetate Tc 99m injection	Radioactive precursor added at the point of use	Supplied separately and not part of the nonradioactive vial
Reconstitution medium	Enables dissolution and labeling	Must meet applicable radiopharmaceutical and sterile-compounding requirements

The commercial formulation strategy is therefore functional rather than consumer-oriented. The excipients must support:

1. Rapid dissolution after reconstitution.
2. High radiochemical purity.
3. Low free technetium and low hydrolyzed-reduced technetium.
4. Adequate stability during the usable post-labeling period.
5. Low particulate burden.
6. Compatibility with technetium Tc 99m eluate.
7. Consistent performance across radiopharmacy sites.

The product’s value does not come from adding conventional fillers, flavors, preservatives, or controlled-release excipients. The formulation must minimize components that could interfere with complexation, biodistribution, sterility, or gamma-camera imaging.

How does stannous chloride function in CHOLETEC?

Stannous chloride is the critical radiolabeling excipient. Technetium is supplied as sodium pertechnetate in a high oxidation state. Stannous ion reduces technetium to a lower oxidation state that permits coordination with mebrofenin.

The ratio between mebrofenin and stannous chloride must be controlled. Excess reducing agent can affect chemical stability or generate undesirable technetium species. Insufficient reducing capacity can reduce labeling efficiency and increase free technetium.

For a commercial competitor, the key development targets are:

• Radiochemical purity after reconstitution.
• Labeling efficiency across the intended activity range.
• Stability over the labeled product’s approved use period.
• Performance with technetium eluates of varying age and activity.
• Resistance to oxygen, light, temperature, and handling variation.
• Reproducibility after transport and storage.

A formulation change involving the reducing agent is not a routine excipient substitution. It can change the finished radiopharmaceutical’s biodistribution and requires comparative analytical and, where applicable, clinical or regulatory support.

What formulation attributes create commercial opportunities?

The strongest formulation opportunities are improvements that reduce radiopharmacy failure risk without changing the approved clinical use.

Longer shelf life for the nonradioactive kit

CHOLETEC is a lyophilized product. A manufacturer could compete on:

• Longer refrigerated or controlled-room-temperature shelf life.
• Better moisture-barrier packaging.
• Improved stopper and vial compatibility.
• Reduced sensitivity to temperature excursions.
• More reliable reconstitution after extended storage.

Longer shelf life can reduce wastage because radiopharmacies order kits around imaging schedules and technetium availability. The economic benefit is greatest for lower-volume hospitals and facilities without full-time nuclear medicine operations.

Faster reconstitution

A kit that dissolves rapidly and consistently can improve workflow in a short half-life environment. Technetium Tc 99m has a physical half-life of approximately six hours, so delays between elution, labeling, quality control, and administration directly reduce available activity [2].

A competitor could assess:

• Time to complete dissolution.
• Need for manual agitation.
• Residual material after reconstitution.
• Compatibility with automated or semi-automated radiopharmacy systems.
• Reduction in failed or repeated preparations.

The commercial claim must remain tied to validated performance. Faster reconstitution alone does not create value if radiochemical purity or post-labeling stability is inferior.

Improved labeling robustness

Radiopharmacies operate with variable technetium eluate conditions. A formulation with a broader operating window could have practical value if it maintains radiochemical purity despite differences in:

• Eluate age.
• Activity concentration.
• Generator performance.
• Vial withdrawal technique.
• Reconstitution volume.
• Ambient temperature.

This opportunity is technically attractive but requires strong comparative data. A manufacturer would need to demonstrate that the revised formulation is equivalent or clinically appropriate under the proposed regulatory pathway.

Lower residual activity and waste

Radiopharmaceutical kits are used in a time-sensitive setting. Residual activity in vials, syringes, or preparation equipment contributes to dose waste and occupational handling. Packaging and vial geometry can be optimized to improve recovery of the labeled product.

Potential improvements include:

• Low-dead-volume vial formats.
• Optimized stopper puncture performance.
• More efficient reconstitution volumes.
• Reduced adsorption to vial or syringe surfaces.
• Packaging compatible with dose-dispensing equipment.

These changes may be commercially relevant even when the active ligand remains unchanged.

What manufacturing and intellectual-property barriers affect CHOLETEC competition?

The active ingredient and basic formulation technology are mature. The main barriers are manufacturing validation, sterile production, radionuclide handling, quality systems, and regulatory comparability.

Manufacturing barriers

A competing manufacturer must control:

• Mebrofenin identity, purity, and impurity profile.
• Stannous chloride content and oxidation state.
• Lyophilization cycle performance.
• Residual moisture.
• Sterility and bacterial endotoxins.
• Container-closure integrity.
• Reconstitution performance.
• Radiochemical purity after technetium labeling.
• Stability of the labeled preparation.
• Distribution under time and temperature constraints.

The product’s operational complexity is higher than that of a conventional sterile injectable because the final radioactive product is prepared at or near the point of administration. The sponsor must validate both the kit and the labeling process.

Patent position

CHOLETEC was approved decades ago. Core composition, mebrofenin use, and basic kit technology are unlikely to provide a commercially meaningful period of exclusivity today. A current competitor would more likely encounter:

• Expired composition and formulation patents.
• Limited or no meaningful Orange Book patent barrier for the core kit.
• Possible manufacturing, packaging, process, or device patents.
• Trade secrets involving lyophilization, quality control, or supply-chain execution.
• Regulatory exclusivity considerations that depend on the approved product and pathway.

Patent clearance must be performed against current USPTO records, FDA Orange Book listings, and the sponsor’s active product-specific filings. A formulation improvement could generate new patent claims, but the claims would need to cover a genuine technical distinction, such as a defined excipient ratio, stability profile, container system, or labeling performance.

What is the FDA regulatory status of CHOLETEC?

CHOLETEC is an FDA-approved prescription diagnostic radiopharmaceutical kit. The FDA label identifies the product as a kit for the preparation of technetium Tc 99m mebrofenin injection [1].

Radiopharmaceutical development must address both the drug product and the radioactive labeling process. The regulatory package generally requires controls for:

• Identity and strength.
• Radiochemical purity.
• Sterility and endotoxins.
• Radionuclidic purity.
• Stability.
• Dose calibration.
• Container closure.
• Manufacturing reproducibility.
• Clinical performance or an appropriate bridge to the reference product.

A competitor’s pathway may depend on whether it is developing a pharmaceutically equivalent kit, a reformulated product, a new diagnostic radiopharmaceutical, or a product relying on a different regulatory route. The distinction affects the scope of required comparative data.

Is CHOLETEC subject to Orange Book listing?

FDA-approved drug products may have patent and exclusivity information listed in the Orange Book when the relevant requirements are met. For a mature radiopharmaceutical kit, the commercial assessment should verify the current FDA listing rather than assume that historical patents remain active.

The practical questions are:

1. Is CHOLETEC currently listed as a prescription drug product?
2. Are any patents listed against the reference product?
3. Are listed patents active or expired?
4. Is regulatory exclusivity still present?
5. Can a competitor file an ANDA or must it pursue another pathway?
6. Would a Paragraph IV certification be required?

A Paragraph IV challenge is commercially relevant only if an unexpired, listed patent creates a filing barrier. For a product with no active listed patents, the competitive focus shifts to approval timing, manufacturing readiness, and market access.

When does CHOLETEC lose exclusivity?

CHOLETEC’s core commercial exclusivity is expected to be limited by the age of the product. Its market position is more likely protected by technical know-how, installed radiopharmacy relationships, supply reliability, and regulatory execution than by an active foundational patent.

The relevant exclusivity categories are:

Exclusivity type	Relevance to CHOLETEC
New chemical entity exclusivity	Unlikely to remain relevant for a mature product
New clinical investigation exclusivity	Depends on later qualifying changes
Orphan exclusivity	Not the principal protection for hepatobiliary imaging
Pediatric exclusivity	Product-specific and time-limited
Patent exclusivity	Must be verified against current Orange Book data
Trade-secret protection	Potentially relevant for manufacturing and quality systems
Supply-chain advantage	Commercially important despite not being legal exclusivity

The absence of meaningful patent exclusivity does not ensure immediate generic entry. Radiopharmaceutical competitors must still establish an approved manufacturing site, qualified suppliers, isotope access, validated release testing, and distribution coverage.

What generic entry risks exist for CHOLETEC?

Generic or follow-on entry risk is moderate from an intellectual-property perspective but constrained by operational requirements.

Near-term entry risks

A competitor could enter through an equivalent kit if it can demonstrate:

• Comparable composition.
• Comparable labeling performance.
• Equivalent or acceptable radiochemical purity.
• Comparable biodistribution and imaging utility.
• Adequate sterile manufacturing.
• Reliable commercial supply.

The most credible entrant would likely be an established radiopharmaceutical company rather than a conventional oral-generic manufacturer. The required capabilities include isotope logistics, nuclear pharmacy relationships, short-dated inventory management, and radioactive product quality control.

Generic launch scenarios

Scenario	Commercial effect
One approved competitor	Price pressure and account-level contracting
Multiple equivalent kits	Greater substitution and formulary competition
Hospital or health-system sourcing	Increased emphasis on supply continuity and service
Regional radiopharmacy competitor	Local price and delivery pressure
Shortage of the reference product	Rapid uptake of available alternatives
Improved formulation with longer shelf life	Reduced waste and broader use in low-volume centers

A first entrant may obtain an advantage by securing group purchasing organization contracts, radiopharmacy distribution agreements, and hospital protocols before additional suppliers enter.

Which companies could challenge or compete with CHOLETEC?

Competition is likely to come from specialized nuclear medicine and radiopharmaceutical manufacturers, hospital radiopharmacies, and suppliers of alternative hepatobiliary imaging agents.

Relevant competitive categories include:

• Bracco Diagnostics and its radiopharmaceutical portfolio.
• Cardinal Health Nuclear & Precision Health Solutions.
• Curium, depending on product and geographic market.
• Jubilant Radiopharma.
• NorthStar Medical Radioisotopes and other isotope-focused suppliers.
• Regional hospital-based radiopharmacies.
• Manufacturers of alternative iminodiacetic acid derivatives.

The competitive threat is not limited to an identical mebrofenin kit. Substitution may occur through alternative hepatobiliary agents, ultrasound, computed tomography, magnetic resonance imaging, or other diagnostic pathways. However, the choice of imaging modality depends on clinical indication, institutional capability, reimbursement, urgency, and physician preference.

How does CHOLETEC compare with alternative hepatobiliary agents?

CHOLETEC belongs to the iminodiacetic acid, or IDA, class of hepatobiliary radiopharmaceuticals. Other agents in the category have been used for similar imaging applications, but the competitive position depends on local availability and regulatory status.

Factor	CHOLETEC	Alternative IDA agent
Ligand	Mebrofenin	Different IDA derivative
Imaging purpose	Hepatobiliary function and biliary anatomy	Similar, depending on product
Main differentiation	Established clinical use and commercial familiarity	Availability, price, or local protocol
Formulation issue	Mebrofenin-stannous kit performance	Agent-specific labeling behavior
Substitution barrier	Protocol familiarity and physician preference	Need for validation and clinical acceptance
Supply risk	Technetium and kit availability	May provide a backup if approved and available

Mebrofenin has high hepatic extraction and is used in hepatobiliary imaging. The commercial value of an alternative depends on whether it delivers comparable imaging quality, workflow, and reimbursement without requiring substantial protocol changes.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve manufacturing and distribution than a novel active pharmaceutical ingredient.

Potential transaction structures include:

Regional commercialization licenses

A company with an approved or near-approved kit could license regional rights to a radiopharmaceutical distributor with established nuclear pharmacy coverage. This model can reduce the capital required to build a direct sales and delivery network.

Contract manufacturing

A sponsor could outsource:

• Mebrofenin synthesis.
• Kit filling.
• Lyophilization.
• Sterility testing.
• Release testing.
• Packaging and labeling.

The contract must address batch release, change control, isotope compatibility, deviations, and supply continuity.

Technology licenses

A formulation or manufacturing license could cover:

• Lyophilization cycles.
• Low-residual-activity vial design.
• Automated reconstitution.
• Radiochemical quality-control methods.
• Stability-enhancing packaging.

The commercial value of such rights depends on whether the technology improves measurable performance and is protected by enforceable claims.

Supply agreements

Long-term supply agreements with technetium generator suppliers, radiopharmacy networks, and hospital systems can be more important than conventional patent licenses. These contracts may determine whether the kit is consistently available within the product’s short operational window.

What revenue exposure does CHOLETEC create?

Public revenue attributable specifically to CHOLETEC is not generally disclosed in standard product labeling. Its commercial exposure is best assessed through procedure volume, product utilization, reimbursement, and supply concentration rather than brand revenue alone.

Key revenue drivers include:

• Number of hepatobiliary studies performed.
• Share of studies using technetium Tc 99m mebrofenin.
• Hospital nuclear medicine capacity.
• Emergency and inpatient gallbladder imaging.
• Radiopharmacy delivery radius.
• Product wastage from unused or failed preparations.
• Contracting with hospital systems and group purchasing organizations.
• Availability of alternative imaging modalities.

The product is especially exposed to supply interruptions because the kit and radionuclide must be available at the time of imaging. A shortage can shift demand quickly to alternative agents or modalities.

What excipient strategy is most attractive for a CHOLETEC competitor?

The strongest strategy is a low-change, high-reliability formulation. A competitor should avoid unnecessary excipient complexity and focus on measurable performance.

Recommended product-development priorities

1. Maintain mebrofenin and stannous chloride as the core functional components unless a clear technical advantage supports change.
2. Optimize the lyophilization cycle for residual moisture and reconstitution time.
3. Validate performance across a broad range of technetium eluate conditions.
4. Improve container closure and moisture protection.
5. Reduce residual activity and product loss during preparation.
6. Establish an extended shelf-life claim if supported by stability data.
7. Design packaging for hospital radiopharmacy workflows.
8. Generate comparative radiochemical and imaging data against the reference product.
9. Protect any real formulation improvement with composition, process, packaging, or use claims.
10. Build a distribution model that matches the six-hour technetium decay environment.

The commercial thesis is operational. An equivalent product that is easier to prepare, less wasteful, and more reliably supplied can compete even without a novel excipient platform.

Key Takeaways

• CHOLETEC is a technetium Tc 99m mebrofenin kit for hepatobiliary imaging.
• Mebrofenin is the imaging ligand; stannous chloride dihydrate is the essential reducing agent.
• The formulation opportunity is concentrated in lyophilization, reconstitution, labeling robustness, packaging, and waste reduction.
• The core product is mature, so patent-based exclusivity is likely less important than regulatory and manufacturing execution.
• Generic entry risk is operationally constrained but not necessarily blocked by foundational patents.
• The most credible competitors are specialized radiopharmaceutical manufacturers and radiopharmacy networks.
• Licensing value is likely to arise from regional distribution, contract manufacturing, formulation technology, and isotope supply arrangements.
• Commercial success depends on radiochemical purity, isotope logistics, hospital workflow, supply continuity, and contracting.

FAQs

Can CHOLETEC be reformulated with a different reducing agent?

Yes, but changing the reducing agent would require comparative development work because the excipient directly affects technetium labeling, radiochemical purity, stability, and biodistribution.

Does CHOLETEC contain a preservative?

The product is supplied as a sterile lyophilized kit for reconstitution and is not positioned as a conventional multidose preservative-containing injectable. The exact inactive-ingredient statement should be taken from the current FDA label and approved product documentation [1].

Can a generic manufacturer use the same mebrofenin formulation?

A competitor may pursue an equivalent formulation, subject to FDA requirements for pharmaceutical equivalence, labeling performance, sterility, radiochemical purity, and the applicable approval pathway.

Is technetium Tc 99m part of the CHOLETEC kit?

No. The kit contains the nonradioactive components. Sodium pertechnetate Tc 99m injection is added during preparation at the radiopharmacy or healthcare facility.

What is the largest commercial risk for a CHOLETEC competitor?

The largest risk is unreliable supply and preparation performance. A product that lacks dependable isotope access, rapid release testing, or time-sensitive distribution may fail commercially even if its formulation is technically equivalent.

References

1. U.S. Food and Drug Administration. (n.d.). CHOLETEC (kit for the preparation of technetium Tc 99m mebrofenin injection) prescribing information. FDA Drugs@FDA.

2. U.S. Nuclear Regulatory Commission. (n.d.). Technetium-99m and medical use of radioactive materials. U.S. Nuclear Regulatory Commission.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.